# Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma

> **NCT03466827** · PHASE2 · UNKNOWN · sponsor: **Morten Mau-Soerensen** · enrollment: 25 (estimated)

## Conditions studied

- Thymoma
- Advanced Thymic Epithelial Tumour

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT03466827
- **Lead sponsor:** Morten Mau-Soerensen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-12
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2018-03-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03466827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03466827, "Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03466827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*